Benefit assessment of preventive medical check-ups in patients suffering from chronic granulomatous disease (CGD)

Research output: Contribution to journalResearch articleContributedpeer-review



Background Chronic granulomatous disease (CGD) patients are susceptible to recurrent opportunistic infections and to recurrent or chronic inflammations of presumably non-infectious origin. Both types of manifestations are often accompanied by granuloma formation. Both can remain unnoticed until they deteriorate considerably and can become life-threatening if not treated in time.

Objective To evaluate the effectiveness of regular follow-up  visits  in  CGD  patients. 

Methods Findings of imaging (ultrasound, radiographs, computer-tomography, magnetic resonance imaging), lung function tests, histopathological and microbiological assessments of biopsies  have  been  reviewed. 

Results A total of 32 CGD patients have been evaluated within 15 years. Of these eight patients have been checked regularly for more than 5 years. Early detection prior to specific clinical signs and consecutive treatment of six lung manifestations and one liver manifestation such as interstitial pneumonia with formation of small granulomas, formation of large granulomas, fibrosis, Aspergillus infections, and abscesses could presumably prevent considerable aggravation in seemingly healthy or mildly symptomatic patients. In contrast, patients without surveillance who presented with severe symptoms (seven manifestations)  often  had  irreversible  organ  damage  or  even  died.

Conclusions Regular follow-up visits can help prevent or mitigate clinical manifestations, improve life quality and expectancy and weigh indication for bone marrow transplantation in CGD patients.


Original languageEnglish
Pages (from-to)513-521
Number of pages9
JournalJournal of evaluation in clinical practice
Issue number6
Publication statusPublished - 30 Nov 2005

External IDs

researchoutputwizard legacy.publication#9162
researchoutputwizard legacy.publication#14402
Scopus 29044448306
ORCID /0000-0002-3666-7128/work/147143657



  • BMT, clinical management, gp91-phox, p47-phox, prednisolone, pulmonary fibrosis